Delali Attiogbe Attipoe is the Chief Operating Officer (COO) for 54gene, a genomics research, services, and development company addressing the need to include under-represented African genomic data in research which could lead to medical breakthroughs and new healthcare solutions worldwide. She joined 54gene with over 15 years of experience in the pharmaceutical sector ranging from logistics and supply chain management to commercial marketing and managed care. Prior to 54gene, Delali was most recently the Head of Market Access for East Africa within Roche Pharmaceuticals (F. Hoffmann La-Roche AG) as well as held former roles of increasing responsibility within Genentech (a US subsidiary of the Roche group).
 
A significant portion of her career and personal passion has focused, and continues to focus, on better affordability and accessibility of diagnostics, treatments, and services for patients within the healthcare sector. She also sits on the board of ReSurge International, a non-profit focused on training surgeons on life-saving reconstructive surgery and providing quality surgical care in developing countries. 
 
In addition to her diverse work background, Delali holds a Bachelors of Science in Biomedical Engineering from the University of Rochester; a Masters in Biotechnology (MB) from the University of Pennsylvania; a Masters in Business Administration (MBA) from Babson College, F.W. Olin School of Business; and received a Certificate in Health Economics and Outcomes Research from the University of Washington.